Apollomics Inc. Warrant (APLMW) Stock Price
APLMWStock
$0.01−46.92%52W
Market Cap$39.03M
P/E—
PEG Ratio—
Div yield—
Beta1.19
APLMW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-58.08%
Price vs S&P 500 (4W)-0.82%
VGM Score45.40
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APLMWApollomics Inc. Warrant | — | — | C | $0.01 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Apollomics Inc. Warrant
Apollomics Inc is a clinical-stage biopharmaceutical company developing oncology therapies that target molecular pathways and enhance immune response. Its lead candidates include vebreltinib, a c-Met inhibitor for non-small cell lung cancer and other c-Met-altered tumors, and uproleselan, an E-Selectin antagonist designed for use with chemotherapy in acute myeloid leukemia.